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Aim: The high incidence of gastrointestinal cancer combined with high mortality from the disease if diagnosed at a late stage, signifies 
the need for better diagnostic, prognostic and predictive tools. Human beta-herpesviruses have been suggested as possible cofactors 
in the development of gastrointestinal cancer. Methods: Sixty five patients with gastrointestinal cancer before surgery and without any 
treatment were enrolled in this study and divided into two groups depending on lymphocytes’ count: I group (n = 35) — lymphocytes 
> 1400x106/L and II group (n = 30) — lymphocytes < 1400x106/L. Nested polymerase chain reaction was used to detect latent and 
active stage of persistent human herpesvirus-6 and -7 infection, laser flow cytometry with monoclonal antibodies — to determine 
immunological parameters. Results: Activation of herpesvirus-6 and -7 was more frequently observed in the patients’ group with lym-
phopenia (HHV-6 1/1 (100%), HHV-7 4/8 (50%) and HHV-6 + HHV-7 6/9 (66%); p < 0.05). Cellular immune parameters were 
analysed in immunocompromised II group’s patients dependently on beta-herpevirus infection. Although number of leukocytes was 
higher in patients with active HHV-6/-7 infection (p = 0.01), number of lymphocytes CD3+, CD4+, CD8+ and CD38+ in patients 
with active HHV-6/-7 infection tended to decrease (p < 0.0001, P = 0.0002, p = 0.0001 and p < 0.0001, respectively). However, 
number of CD19+ had tendency to increase (p = 0.03). Conclusion: Activation of herpesvirus-6 and -7 may lead to decrease of lym-
phocytes total count and develop immunosuppression in patients with gastrointestinal cancer.
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Gastrointestinal cancer �GIC� �s�ally develops 
from a benign polyp thro�gh an adenoma with dys-
plasia into a carcinoma with metastatic potential. 
The late diagnosis of this disease often leads to the 
high incidence of patients’ death. This signifies the 
need for better diagnostic� prognostic and predictive 
tools. The emergence of knowledge on the molec�lar 
level has gained insight in ca�ses for initiation and 
progression of t�mo�r development. This knowledge 
has also revealed the complexity and heterogeneity 
of the disease� explaining why only few biomarkers are 
in ro�tine clinical �se. GIC is the second and third most 
commonly diagnosed cancer in the world for women 
and men� respectively. Approximately half of GIC pa-
tients develop metastatic disease [�].
H�man herpesvir�s-� �HHV-�� and h�man herpes-
vir�s-7 �HHV-7� are �biq�ito�s beta-herpesvir�ses [�]. 
Both are widely distrib�ted in the general pop�lation 
and primary infection �s�ally occ�rs in the early years 
of life and remains latent in the host for the lifelong 
period [�]. These vir�ses can be reactivated in im-
m�nos�ppressed conditions and can lead to severe 
complications in patients with solid organ transplan-
tation [4]. Malignancy also is associated with imm�-
nos�ppression in hematological t�mors and in solid 
organ cancers as well.
HHV-� and HHV-7 share a high degree of genomic 
homology and have some similar biological proper-
ties. Th�s� these herpesvir�ses might share a similar 
oncogenic potential [�]. For both� HHV-� and HHV-7� 
main target cells appeared to be CD4+ lymphocytes� 
b�t nat�ral killer cells� CD8+ T cells� macrophages� 
epithelial� endothelial� ne�ral cells and fibroblasts may 
also be infected [�� 7].
HHV-� has imm�nomod�lating properties and 
is a powerf�l ind�cer of cytokines. One important mecha-
nism of HHV-� pathogenesis is the engagement of the 
primary viral receptor� CD4�� a complement-reg�latory 
cell s�rface molec�le that provides a key link between 
innate and adaptive imm�ne responses [8]. Recently 
it was shown that expos�re to HHV-� res�lts in a dramatic 
inhibition of IL-�� p7� prod�ction by differentiated h�man 
macrophages in the absence of a prod�ctive viral infec-
tion� a phenomenon that is likely mediated by CD4� en-
gagement [�]. Other mechanisms of imm�ne dereg�la-
tion by HHV-� incl�de defective antigen presentation 
by dendritic cells and aberrant cytokine prod�ction by pe-
ripheral blood monon�clear cells� s�ch as an increased 
secretion of IL-�β� t�mor necrosis factor alpha �TNF-α�� 
and IL-�� and a decreased secretion of IL-� associated 
with diminished cell�lar proliferation [�����]. Persistent� 
IL-� reg�lated� HHV-� infection of ad�lt T-cell le�kemia 
cells ca�ses T cell le�kemia to progress more rapidly� b�t 
in vivo st�dies a pathogenic role for HHV-� in this disease 
has not been yet confirmed [��]. Vir�s-ind�ced changes 
in cytokines secretion can lead to changes in t�mor mi-
croenvironment and deviation of anti-t�mo�r imm�ne re-
sponse. HHV-� may also contrib�te to cancer circ�ito�sly 
thro�gh imm�ne s�ppression. HHV-� can directly infect 
CD4+ T-cells and ind�ce apoptosis� as an effective CD4+ 
T cells response is believed to prevent tolerance ind�ction 
by t�mor antigen [�4���].
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Despite of HHV-7 and HHV-� similarities� important 
differences between these vir�ses exist� incl�ding the 
fact that HHV-7 binds to the cell�lar CD4+ molec�le 
and �ses this protein as a necessary component of its 
receptor� while HHV-� binds to a different receptor. F�r-
thermore� the pathogenesis and seq�elae of HHV-7 in-
fection remains very poorly �nderstood [�7].
MATERIALS AND METHODS
Patients �n = ��� with histologically confirmed 
vario�s stages of gastrointestinal cancer �GIC� were 
aged from �� to 8� years. The cohort was established 
with the approval of the Ethics Committee of the Riga 
Stradins University and all participants gave their in-
formed consent prior to the examination. Blood was 
drawn before s�rgery and any antit�mor treatment� 
patients were divided into two gro�ps depending 
on lymphocyte co�nt: I gro�p �n = ��� — lymphocytes 
> �4�� x���/L and II gro�p �n = ��� — lymphocytes < 
�4�� x���/L. Imm�nological parameters were deter-
mined by Becton Dickinson �USA� laser flow cytofl�o-
rimeter �sing corresponding monoclonal antibodies 
to lymphocyte s�bpop�lations: CD�+� CD4+� CD8+� 
CD�8+� CD��+� CD��+� CD��+ and CD��+.
Nested polymerase chain reaction �nPCR� was �sed 
for the detection of persistent infection �viral genomic 
seq�ences in whole blood DNA� and active phase �viral 
genomic seq�ences in cell free plasma DNA� of persis-
tent HHV-� and HHV-7 infection. Total DNA was isolated 
from �.� ml of fresh whole blood by phenol-chloroform 
extraction. For DNA p�rification from ��� µl of cell free 
blood plasma QIAamp Blood Kit �QIAGEN� Germany� was 
�sed. The plasma samples were treated with Deoxyribo-
n�clease I before DNA p�rification. To ass�re the q�ality 
of the whole blood DNA as well as to excl�de contami-
nation of plasma DNA by cell�lar DNA� globin PCR was 
performed. PCR amplification for the vir�ses was car-
ried o�t in the presence of � µg of whole blood DNA and 
�� µl of plasma DNA �corresponding to ��� µl of plasma�. 
The detection of HHV-� and HHV-7 DNA was performed 
according to Secchiero et al. ������ and Berneman et al. 
������� respectively. Positive �vir�ses genomic DNA� 
ABI� USA� and negative �DNA witho�t vir�s-specific se-
q�ences� as well as water controls were incl�ded in each 
experiment.
HHV-� variants were identified �sing restriction 
endon�clease analysis. The restriction enzyme HindIII 
�Fermentas� Lith�ania�� which c�ts the ���-bp HHV-�B 
amplimer into two fragments of �� and �7 bp� b�t does 
not c�t the HHV-�A amplimer was �sed for this p�rpose.
HHV-� specific antibody testing in the plasma 
samples was carried o�t �sing HHV-� IgG ELISA 
kit �Panbio� A�stralia� according to the man�fac-
t�rer’s recommendations.
H�man TNF-α� IL-�β� sIL �R: Solid-phase� two-site 
chemil�miniscent imm�nometric assay �Imm�lite� SIE-
MENS� USA�. IL-�: solid-phase� enzyme-labeled chemi-
l�miniscent seq�ential imm�nometric assay �Imm�lite 
SIEMENS� USA� according to the man�fact�rer’s rec-
ommendations. All samples were tested in d�plicates.
Statistical difference in the prevalence of latent 
and active HHV-� and HHV-7 infection was as-
sessed by Fisher’s exact test. St�dent’s t-test was 
�sed to compare significance in changes of plasma 
cytokines’ levels and cell co�nts. For the prediction 
of lymphopenia regression analysis was �sed.
RESULTS
Comparative analysis of cell�lar imm�ne pa-
rameters in both imm�nocompetent �lymphocytes 
> �4��x���/L� and imm�nocompromised �lympho-
cytes < �4��x���/L� GIC patients gro�ps showed sig-
nificant differences in almost all rates independently 
of beta-herpesvir�ses infection. The mean absol�te 
n�mber of lymphocytes in the I gro�p was two times 
���%� higher than in the II gro�p ���7� ± 7��x���/L; 
��4� ± ��� x ���/L� respectively; p = �.����� �Table ��. 
However� the mean n�mber of le�kocytes in the II gro�p 
�7��� ± ���� ���/L� was significantly �p = �.���� higher 
��7%� than in the I gro�p ��8�� ± ����x���/L�. Com-
parative analyses of the lymphocyte s�bsets between 
the I and II gro�p �CD�+� CD4+� CD8+� CD�8+� CD��+� 
CD��+� CD��+ and CD��+� showed significant de-
crease of imm�nological parameters in the II gro�p — 
approximately two times decrease in comparison with 
the I gro�p �Table ��.
Table 1. Immunological parameters in the I and II patients groups
Parametrs
Group I Ly > 1400 (n=35) Group II Ly < 1400 (n=30)
p ≤ 0.05Absolute 
count ± SD Count, %
Absolute 
count ± SD Count, %
Leu 7910 ± 1960 5830 ± 2210 0.002
Mo 650 ± 170 8.44 440 ± 220 7.87 0.0005
Ly 2270 ± 700 28.83 1140 ± 210 19.88 0.0001
CD3+ 1600 ± 580 70.77 780 ± 180 70.77 0.0001
CD4+ 880 ± 330 39.29 450 ± 130 39.0 0.0001
CD8+ 680 ± 370 29.11 330 ± 120 31.08 0.0001
CD38+ 660 ± 300 29.03 320 ± 90 28.4 0.0001
CD16+ 460 ± 310 19.69 220 ± 130 19.4 0.0015
CD19+ 190 ± 110 8.03 110 ± 60 7.0 0.0018
CD95+ 1130 ± 370 50.89 520 ± 130 48.8 0.0001
CD25+ 180 ± 150 8.63 80 ± 50 7.5 0.047
CD4+/
CD8+
1.58 ± 0.85 1.18 ± 0.57 0.03
Virological st�dies showed that 44 o�t of �� ��8%� 
GIC patients had persistent beta-herpesvir�ses 
infection. HHV-� genomic seq�ence was detected 
in ��/�� ���%�� when presence of anti-HHV-� specific 
IgG class antibodies was detected in ��/�� ���%� 
patients. HHV-7 genomic seq�ence was fo�nd 
in 4�/�� ���%� patients DNA. Freq�ency of single 
HHV-7 persistent infection was significantly higher 
�p = �.���� in the I gro�p ��/�� ��7%� than in the 
II gro�p 8/�� ��7%�� when do�ble �HHV-� + HHV-
7� persistent infection was significantly �p = �.�4�� 
higher in the II gro�p �/�� ���%� than in the I gro�p 
4/�� ���%�. However� single HHV-� persistent infec-
tion was detected only in one I gro�p’s patient and 
in two patients of the II gro�p �Table ��. Nonetheless� 
HHV-7 genomic seq�ence was fo�nd only in � o�t 
of �� ���%� plasma DNA samples of CIG patients of the 
I gro�p. In contrast� activation of HHV-7 was fo�nd 
in 4 o�t of 8 ���%� patients of the II gro�p. F�rther-
more� sim�ltaneo�s activation of both vir�ses �HHV-� + 
HHV-7� was significantly more often detected in the 
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II gro�p’s patients ��/� ���%�; p < �.��� �Table ��. 
In all HHV-� positive DNA samples isolated from GIC 
patients’ white blood cells and plasma HHV-�B variant 
was identified.
Table 2. Distribution of latent and active beta-herpesviruses (HHV-6 and 
HHV-7) infection
HHV-6 la-
tent/active 
infection
HHV-7 la-
tent/active 
infection
HHV-6 + 
HHV-7 la-
tent/active 
infection
Without 
HHV-6 or   
HHV-7 in-
fection
I patients group (n = 35) 1/0 17/3 4/0 10
II patients group (n = 30) 1/1 4/4 3/6 11
Comparative analysis of cell�lar imm�ne parame-
ters in the I and II gro�p was performed dependently 
of beta-herpevir�ses infection. Each gro�p was s�b-
divided into three s�bgro�ps: GIC patients witho�t� 
with latent and with active HHV-� and/or HHV-7 infec-
tion. In the I gro�p patients with active viral infection 
had tendency to increase all cell�lar imm�nological 
parameters �le�kocytes� monocytes� lymphocytes 
and CD�+� CD4+� CD8+� CD�8+� CD��+� CD��+� CD��+� 
CD��+� comparing with the s�bgro�ps with latent and 
witho�t HHV-� and HHV-7 infection. Altho�gh n�mber 
of le�kocytes in the II gro�p with active HHV-�/-7 in-
fection was higher than in other s�bgro�ps� n�mber 
of lymphocytes� CD�+� CD4+� CD8+ and CD�8+ cells 
had tendency to decrease. However� n�mber of CD��+ 
cells had tendency to increase �Table ��. The logistic 
regression analysis showed that patients with active 
viral infection have higher risk of lymphopenia �OR �.��� 
��% CI �.7����.��; p = �.����� than patients with latent 
viral infection �OR �.��� ��% CI �.����.�7; p = �.�����.
There were no significant changes in the ser�m 
levels of IL-�� IL-�β� sIL-�R and TNF-α between GIC 
patients of the I and II gro�p. However� in the I and 
II gro�p of patients with active viral infection the levels 
of IL-� and sIL-�R had tendency to increase� none-
theless� level of TNF-α in the II gro�p was lower than 
in patients with latent and witho�t viral infection� and 
also lower in comparison to the I gro�p’s patients with 
active viral infection �Table 4�.
DISCUSSION
At the moment there is little information abo�t in-
fl�ence of beta-herpesvir�ses infection on the co�rse 
of disease in patients with GIC. Gastrointestinal malig-
nancies are associated with a compromised imm�ne 
system and vir�ses� s�ch as imm�notropic and imm�-
nomod�lating HHV-� and HHV-7 may be able to �tilize 
cell�lar mechanisms responsible for the imm�ne 
response inhibition. Mod�lation of f�nctional proper-
ties of host imm�ne factors is an important mechanism 
of evading the imm�ne response or creating an envi-
ronment in which the vir�s can s�rvive. O�r res�lts have 
shown that in GIC patients gro�p with lymphopenia the 
activation of HHV-� and HHV-7 infection is significantly 
more freq�ent �p = �.����. In all HHV-� positive pa-
tients HHV-�B variant was detected. This corresponds 
with the data demonstrated by Lempinen et al. [�8]. 
Proportionally balance of lymphocytes s�bpop�lations 
in both gro�ps was identical� however� lymphopenia 
was observed in the II gro�p’s patients� which co�ld 
be closely related with the higher rate of activation 
of beta-herpesvir�s infection. S�ch interaction co�ld 
lead to the worst o�tcomes. However� absol�te co�nt 
of le�kocytes in the II gro�p patients with active viral 
infection increases� preferable beta-herpesvir�s 
cell target pop�lations are decreased �lymphocytes 
absol�te co�nt and CD�+� CD8+ and CD�8+ s�bpop�-
lations�. S�ch difference in cell pop�lations co�ld 
be another evidence of HHV-� and HHV-7 involve-
ment in this disease progression. Another interesting 
observation is noticed in nat�ral killers’ pop�lation 
�CD��+�� which do not increase even in patients with 
active viral infection. This abnormal anti-viral response 
co�ld lead to worse progression of co-infections and 
worst o�tcomes in GIC patients.
There are no significant changes observed in ser�m 
levels of IL-�� IL-�β� sIL-�R and TNF-α between GIC 
patients of the I and II gro�ps with latent and witho�t 
HHV-�/-7 infection� b�t in the II gro�p’s patients 
with active viral infection level of TNF-α is decreased 
comparing to the other gro�ps. However� it was hard 
Table 3. Average count of immunocompetent cells in the I group and II group patients
Para metrs Without HHV-6/-7 p HHV-6/-7 latent p HHV-6/-7 active pGroup I (n = 10) Group II (n = 11) Group I (n = 22) Group II (n = 8) Group I (n = 3) Group II (n = 11)
Leu 7670 ± 1610 5420 ± 2480 0.02 7720 ± 2050 5800 ± 2090 0.03 10030 ± 1420 6310 ± 2110 0.01
Mo 650 ± 130 490 ± 290 0.0007 610 ± 140 320 ± 50 < 0.0001 930 ± 280 420 ± 190 0.003
Ly 2260 ± 870 1130 ± 230 0.0005 2110 ± 490 1230 ± 60 < 0.0001 3400 ± 420 1070 ± 250 < 0.0001
CD3+ 1580 ± 790 770 ± 140 0.003 1490 ± 360 870 ± 110 0.0001 2500 ± 270 730 ± 240 < 0.0001
CD4+ 890 ± 450 420 ± 120 0.003 850 ± 280 500 ± 50 0.002 1110 ± 240 440 ± 180 0.0002
CD8+ 670 ± 520 340 ± 90 0.052 600 ± 180 370 ± 120 0.002 1190 ± 470 290 ± 130 0.0001
CD38+ 680 ± 320 330 ± 140 0.004 630 ± 300 310 ± 40 0.006 780 ± 160 300 ± 50 < 0.0001
CD16+ 490 ± 330 250 ± 180 0.04 410 ± 320 210 ± 70 0.1 650 ± 190 210 ± 90 0.0001
CD19+ 180 ± 90 80 ± 50 0.004 170 ± 70 110 ± 50 0.04 350 ± 280 130 ± 80 0.03
CD95+ 1170 ± 460 500 ± 100 0.0001 1040 ± 230 570 ± 160 0.0002 1620 ± 230 510 ± 150 < 0.0001
CD25+ 170 ± 100 110 ± 60 0.11 180 ± 180 50 ± 30 0.05 220 ± 90 80 ± 40 0.001
CD4+/CD8+ 1.68 ± 0.85 1.24 ± 0.49 0.16 1.55 ± 0.9 1.31 ± 0.49 0.5 1.37 ± 0.56 1.29 ± 0.65 0.8
Table 4. Levels of IL-1β, IL-6, sIL2R and TNF-α in the I and II group patients*
Patients groups IL-1β (pg/ml); N < 5.0 IL-6 (U/ml); N = 3.4 sIL2R (U/ml); N = 223–710 TNF-α (pg/ml); N = 8.1
Group I (n = 10) Without HHV-6/-7 < 5.0 4.08 ± 1.23 527 ± 159.58 15.13 ± 5.15
Group II (n = 11) Without HHV-6/-7 < 5.0 5.15 ± 2.76 559.80 ± 379.10 15.58 ± 5.66
Group I (n = 22) HHV-6/-7 latent < 5.0 5.44 ± 2.99 604.78 ± 242.33 11.62 ± 1.08
Group II (n = 8) HHV-6/-7 latent < 5.0 5.55 ± 1.91 617.00 ± 173.20 13.83 ± 3.06
Group I (n = 3) HHV-6/-7 active infection < 5.0 7.20 ± 11.88 851 ± 528.55 14.40 ± 5.31
Group II (n = 11) HHV-6/-7 active infection < 5.0 6.18 ± 2.91 733.67 ± 388.76 9.78 ± 4.23
*p > 0.05 for all groups.
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to compare GIC patients with active viral infection 
beca�se of higher HHV-� and HHV-7 distrib�tion 
in the II gro�p and low presence of active infection 
in the I gro�p. Despite of this observation� it is pos-
sible to s�ppose important role of beta-herpesvir�ses 
in GIC development and decreased level of TNF-α and 
increased levels of IL-� and sIL�R in patients with 
active and persistent vir�s infection co�ld confirm 
HHV-� and HHV-7 imm�nomod�lating properties. 
Both facts� decrease in lymphocytes’ s�bpop�lations 
and changes in levels of interle�kins� co�ld show 
possible mechanisms of how HHV-� and HHV-7 in-
fl�ence the co�rse of the disease. First mechanism 
is direct infl�ence on lymphocytes by infecting them 
and ind�cing cell lyses� and second — infl�ence 
thro�gh changes in interle�kins expression. Com-
bining st�dies of both vir�s and cancer mediated 
imm�ne s�ppressive mechanisms will help �s to �n-
derstand the complicated host-t�mo�r interactions. 
The f�rther investigation is important to eval�ate not 
only changes in pro-inflammatory cytokines b�t also 
in anti-inflammatory cytokines expression in patients 
with GIC. It co�ld explain ways of vir�s infl�ence on the 
co�rse of disease and wo�ld help to choose the most 
efficient treatment tactic.
In concl�sion� activation of HHV-� and HHV-7 may 
lead to decrease of lymphocytes’ total co�nt and wors-
ening of imm�ns�ppresion in patients with GIC. High 
freq�ency of beta-herpesvir�ses infection in patients 
with GIC is contrib�ting into increase of IL-�� sIL-�R 
and decrease of TNF-α expression levels what co�ld 
lead to the worse clinical o�tcomes. Estimation of the 
vir�ses-associated impairment of imm�nological f�nc-
tions may be �sef�l for clinical application to monitor-
ing of GIC patients.
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